- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.11. | Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights | 17 | PR Newswire | - Reported positive interim clinical proof-of-concept results for TYRA-300 in mUC from SURF301 Ph1/2 study -
- IND cleared for Phase 2 study of TYRA-300 in pediatric... ► Artikel lesen | |
| 07.11. | Tyra Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.11. | Tyra Biosciences Direktorin Nina Kjellson verkauft Aktien im Wert von 2,28 Millionen US-Dollar | 1 | Investing.com Deutsch | ||
| 28.10. | Tyra Biosciences macht Fortschritte mit Phase-2-Studie für Achondroplasie-Behandlung | 2 | Investing.com Deutsch | ||
| 28.10. | Tyra Biosciences advances with Phase 2 trial for achondroplasia treatment | 2 | Investing.com | ||
| 28.10. | Tyra Biosciences (NASDAQ:TYRA) Sees Strong Trading Volume After Analyst Upgrade | 1 | MarketBeat | ||
| 28.10. | Tyra Biosciences stock target lifted, retains buy on clinical trial data | 2 | Investing.com | ||
| TYRA BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 28.10. | FDA genehmigt Tyra Biosciences' Studie für Kleinwuchs-Medikament | 2 | Investing.com Deutsch | ||
| 28.10. | FDA clears Tyra Biosciences' trial for dwarfism drug | 2 | Investing.com | ||
| 28.10. | Tyra Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.10. | Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301) | 53 | PR Newswire | - TYRA-300 is the first oral FGFR-3 selective inhibitor to be well-tolerated in clinical studies -
- First child with achondroplasia expected to be dosed in Q1 2025... ► Artikel lesen | |
| 25.10. | Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday? | 3 | Benzinga.com | ||
| 25.10. | Tyra Biosciences, Inc.: Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic ... | 63 | PR Newswire | - Encouraging preliminary anti-tumor activity observed in heavily pre-treated population -
- At = 90 mg QD, 6 out of 11 (54.5%) patients with FGFR3+ mUC achieved... ► Artikel lesen | |
| 23.10. | Tyra Biosciences stock soars to 52-week high of $28.86 | 2 | Investing.com | ||
| 23.10. | Tyra Biosciences-Aktie erreicht 52-Wochen-Hoch von 28,86 US-Dollar | 1 | Investing.com Deutsch | ||
| 18.10. | Tyra Biosciences issues warrants in exchange for common stock | 2 | Investing.com | ||
| 18.10. | Tyra Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.10. | BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug | 8 | Benzinga.com | ||
| 18.10. | BofA upgrades Tyra Biosciences shares rating to Buy, raises price target | 4 | Investing.com | ||
| 16.10. | Tyra Biosciences-Aktie erreicht 52-Wochen-Hoch von 25,3 US-Dollar | 3 | Investing.com Deutsch |
Seite:
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 0,900 | -21,74 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,364 | -1,62 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,100 | +0,83 % | Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short Interest | ||
| RECURSION PHARMACEUTICALS | 6,040 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,480 | 0,00 % | Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short Interest | ||
| ONCOLYTICS BIOTECH | 0,950 | +0,53 % | Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2024 Earnings Call Transcript | ||
| ARCTURUS THERAPEUTICS | 16,190 | 0,00 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,950 | 0,00 % | Assertio Holdings-Direktorin Heather Mason kauft Aktien im Wert von 60.000 US-Dollar | ||
| SIGA TECHNOLOGIES | 6,250 | 0,00 % | SIGA Technologies - TPOXX chalks up another DoD contract win | SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for... ► Artikel lesen | |
| ADMA BIOLOGICS | 21,370 | 0,00 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
| VIR BIOTECHNOLOGY | 6,740 | 0,00 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
| VERVE THERAPEUTICS | 4,550 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 16,500 | -2,94 % | Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level | ||
| ARVINAS | 22,690 | 0,00 % | Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode | ||
| BIO-PATH | 0,790 | 0,00 % | Bio-Path Holdings, Inc.: Bio-Path Holdings Reports Third Quarter 2024 Financial Results | Expands DNAbilize® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology... ► Artikel lesen |
TYRA BIOSCIENCES INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 15,870 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TYRA BIOSCIENCES INC finden Sie auf Wallstreet Online.
